Life science technology company PacBio (NASDAQ:PACB), a developer of advanced sequencing solutions, and microbiome research and discovery specialist Intus Bio announced on Friday the launch of GutID, the first commercial human gut health test powered by PacBio's HiFi sequencing technology and Intus Bio's Titan-1 platform.
GutID is designed to provide a comprehensive and accurate analysis of the gut microbiome, including strain-level identification of both beneficial and pathogenic bacteria.
The test utilises PacBio's long-read sequencing technology, enabling high-resolution analysis of the microbiome and delivering robust and repeatable results.
GutID is targeted at individuals seeking to understand and improve their gut health, and is particularly beneficial for those with conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
The test involves a simple at-home sample collection and provides users with a detailed report, including a microbiome health score and personalised recommendations.
Spyre Therapeutics starts dosing in Phase 1 clinical trial of SPY003
IASO Biotherapeutics receives Macau approval for equecabtagene autoleucel NDA
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
AnHorn Medicines' AH-001 enters Phase I clinical trial in US
CytoSite Bio signs collaboration agreement with Lantheus Holdings
Innate Pharma's IPH4502 to be featured at AACR 2025 Annual Meeting
Rafael Holdings completes merger with Cyclo Therapeutics, focuses on lead asset Trappsol Cyclo